These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 12647218)

  • 1. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray.
    Alkushi A; Irving J; Hsu F; Dupuis B; Liu CL; Rijn M; Gilks CB
    Virchows Arch; 2003 Mar; 442(3):271-7. PubMed ID: 12647218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ancillary p16(INK4a) adds no meaningful value to the performance of ER/PR/Vim/CEA panel in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
    Yao CC; Kok LF; Lee MY; Wang PH; Wu TS; Tyan YS; Cheng YW; Kung MF; Han CP
    Arch Gynecol Obstet; 2009 Sep; 280(3):405-13. PubMed ID: 19153755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinguishing between primary endocervical and endometrial adenocarcinomas: is a 2-marker (Vim/CEA) panel enough?
    Liao CL; Hsu JD; Lee MY; Kok LF; Li YJ; Wang PH; Yao CC; Han CP
    Virchows Arch; 2010 Apr; 456(4):377-86. PubMed ID: 20221633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas.
    McCluggage WG; Sumathi VP; McBride HA; Patterson A
    Int J Gynecol Pathol; 2002 Jan; 21(1):11-5. PubMed ID: 11781517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding the p16(INK4a) marker to the traditional 3-marker (ER/Vim/CEA) panel engenders no supplemental benefit in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
    Han CP; Lee MY; Kok LF; Ruan A; Wu TS; Cheng YW; Tyan YS; Lin CY
    Int J Gynecol Pathol; 2009 Sep; 28(5):489-96. PubMed ID: 19696622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progesterone receptor does not improve the performance and test effectiveness of the conventional 3-marker panel, consisting of estrogen receptor, vimentin and carcinoembryonic antigen in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study.
    Liao CL; Lee MY; Tyan YS; Kok LF; Wu TS; Koo CL; Wang PH; Chao KC; Han CP
    J Transl Med; 2009 May; 7():37. PubMed ID: 19476621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma.
    Torenbeek R; Lagendijk JH; Van Diest PJ; Bril H; van de Molengraft FJ; Meijer CJ
    Histopathology; 1998 Jan; 32(1):20-7. PubMed ID: 9522212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p16 INK4 and CEA can be mutually exchanged with confidence between both relevant three-marker panels (ER/Vim/CEA and ER/Vim/p16 INK4) in distinguishing primary endometrial adenocarcinomas from endocervical adenocarcinomas in a tissue microarray study.
    Han CP; Lee MY; Tyan YS; Kok LF; Yao CC; Wang PH; Hsu JD; Tseng SW
    Virchows Arch; 2009 Oct; 455(4):353-61. PubMed ID: 19763614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Diagnosis between Primary Endocervical and Endometrial Adenocarcinoma using Immunohistochemical Staining of Estrogen Receptor, Vimentin, Carcinoembryonic Antigen and p16.
    Yanaranop M; Ayuwat S; Nakrangsee S
    J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S106-15. PubMed ID: 27266224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunohistochemical discrimination of endometrioid adenocarcinomas.
    Dabbs DJ; Sturtz K; Zaino RJ
    Hum Pathol; 1996 Feb; 27(2):172-7. PubMed ID: 8617459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A reappraisal of three-marker (ER/Vim/CEA), four-marker (ER/Vim/CEA/PR), and five-marker (ER/Vim/CEA/PR/p16INK4a) panels in the diagnostic distinction between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
    Han CP; Lee MY; Kok LF; Wu TS; Cheng YW; Wang PH; Yue CH; Tyan YS
    Arch Gynecol Obstet; 2010 May; 281(5):845-50. PubMed ID: 19847454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of ER, VIM, CEA and p16 detection in the diagnosis and differential diagnosis of primary endocervical and endometrial adenocarcinomas].
    Hu WW; Tao JH; Li GM; Xu X; Yang XM
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):526-8, 531. PubMed ID: 20335127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint.
    Kamoi S; AlJuboury MI; Akin MR; Silverberg SG
    Int J Gynecol Pathol; 2002 Jul; 21(3):217-23. PubMed ID: 12068166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas.
    Kong CS; Beck AH; Longacre TA
    Am J Surg Pathol; 2010 Jul; 34(7):915-26. PubMed ID: 20534993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma.
    McCluggage WG; Jenkins D
    Int J Gynecol Pathol; 2003 Jul; 22(3):231-5. PubMed ID: 12819388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone receptor immunohistochemistry and human papillomavirus in situ hybridization are useful for distinguishing endocervical and endometrial adenocarcinomas.
    Staebler A; Sherman ME; Zaino RJ; Ronnett BM
    Am J Surg Pathol; 2002 Aug; 26(8):998-1006. PubMed ID: 12170086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adenocarcinoma of the cervix uteri (immunohistochemistry, ultrastructure, differential diagnosis from adenocarcinoma of the adjacent organs].
    Petrov SV; Raĭkhlin NT; Serre G; Smedts F
    Arkh Patol; 1995; 57(5):47-53. PubMed ID: 8579496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor.
    Yemelyanova A; Vang R; Seidman JD; Gravitt PE; Ronnett BM
    Am J Surg Pathol; 2009 Jun; 33(6):914-24. PubMed ID: 19295407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemistry and HPV in situ hybridization in pathologic distinction between endocervical and endometrial adenocarcinoma: a comparative tissue microarray study of 76 tumors.
    Jones MW; Onisko A; Dabbs DJ; Elishaev E; Chiosea S; Bhargava R
    Int J Gynecol Cancer; 2013 Feb; 23(2):380-4. PubMed ID: 23318908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermediate filaments in endometrial and endocervical carcinomas. The diagnostic utility of vimentin patterns.
    Dabbs DJ; Geisinger KR; Norris HT
    Am J Surg Pathol; 1986 Aug; 10(8):568-76. PubMed ID: 2426982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.